fMRI-based deep brain stimulation programming for Parkinson's disease: a blinded, crossover clinical trial

Brain stimulation 2026 Open access

Read full text
Authors: Brendan Santyr, Alexandre Boutet, Jurgen Germann, Jianwei Qiu, Aaron Loh, Ibrahim Alhashyan, Clement T. Chow, Can Sarica, Artur Vetkas, Andrew Yang, Gavin Elias, Stefan Lang
+5 more Mojgan Hodaie, Suneil K. Kalia, A. Fasano, Afis Ajala, Andres M. Lozano
DOI: 10.1016/j.brs.2026.103069
Cited by: 2
References: 10

Abstract

The therapeutic success of deep brain stimulation (DBS) for Parkinson’s disease (PD) relies on precise titration of stimulation parameters.1 While rigidity and tremor may respond within minutes, other features, including bradykinesia, axial motor signs, and cognitive side effects manifest over days to months.1 Consequently, DBS programming commonly requires prolonged trial-and-error adjustments, often extending over a year.1 This challenge is amplified in emerging DBS indications, such as dystonia, psychiatric conditions, and Alzheimer’s disease, where therapeutic response may be even more delayed.

Fields of Study & Subjects

Neurological disorders and treatments EEG and Brain-Computer Interfaces Parkinson's Disease Mechanisms and Treatments

Publication details

Journal / source
Brain stimulation
Publisher
Elsevier BV
Volume
19
Issue
2
Pages
103069–103069
Publication date
1 March 2026
Language
EN